Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
10:10am, Wednesday, 03'rd Jul 2024
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
04:45pm, Tuesday, 02'nd Jul 2024
Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap
Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial
01:57pm, Tuesday, 02'nd Jul 2024
Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
08:00am, Wednesday, 26'th Jun 2024
MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative th
Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
08:00am, Tuesday, 11'th Jun 2024
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurod
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
10:56am, Tuesday, 28'th May 2024
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
Annovis Announces New Publication in a Peer-Reviewed Journal
07:30am, Tuesday, 21'st May 2024
MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerat
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
11:00am, Friday, 17'th May 2024
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Comp
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio,
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
03:09pm, Thursday, 16'th May 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) on behalf of investors concerning the C
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
07:30am, Monday, 13'th May 2024
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerat
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
08:43pm, Thursday, 09'th May 2024
Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
07:30am, Thursday, 09'th May 2024
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerat
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
07:30am, Monday, 06'th May 2024
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerat
Annovis Bio reports positive results in mid-stage Alzheimer's treatment trial
10:30am, Monday, 29'th Apr 2024
Annovis Bio said on Monday that its Alzheimer's treatment showed significantly higher improvement in cognition in Alzheimer's patients during a mid-stage trial.
